NGHIÊN CỨU MỐI LIÊN QUAN GIỮA ĐÁP ỨNG ĐIỀU TRỊ BƯỚC 2 BẰNG PHÁC ĐỒ PACLITAXEL-CARBOPLATIN VÀ MỘT SỐ ĐẶC ĐIỂM CỦA BỆNH NHÂN UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ

Abstract

Objectives: To study some factors related to the pathological characteristics of non-small cell lung cancer cases with response to second-line treatment with Paclitaxel-Carboplatin regimen. Methods: A cross-sectional descriptive study combining retrospective and prospective on 42 patients with stage IIIB-IV lung cancer at the National Lung Hospital from January 2016 to June 2019. Results: 42.8% of patients had a complete response to the Paclitaxel - Carboplatin chemotherapy regimen. Patients with PS = 0, disease stage IIIB, response time to TKI step 1 out of 6 months have higher Overal response rate (ORR) and long Progression-free survival 2 (PFS2) than the corresponding patient with PS = 1, disease stage IV, response time to TKI step 1 is less than 6 months. The difference was statistically significant with p < 0.05. Other factors such as age group, gender, type of mutation, type of TKI for first-line treatment have not been found to correlate with Overal response rate (ORR) and time of Progression-free survival 2 (PFS2). Conclusion: The factors that positively affect overal response rate (ORR) and Progression-free survival 2 (PFS2) are PS = 0, stage IIIB, response time with TKI > 6 months.